Can a simple device close the diabetes care gap for the uninsured?

NCT ID NCT07135531

Recruiting now Disease control Sponsor: Tulane University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether continuous glucose monitors (CGMs) can improve blood sugar control in underserved people with type 2 diabetes who are uninsured or on Medicaid. Fifty participants will wear a CGM replaced every 14 days for 6 months. The goal is to see if this technology helps reduce health disparities and prevent long-term complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Continuous glucose monitor (CGM) device
What this could lead to: If successful, this could show that CGMs help underserved patients with type 2 diabetes better manage their blood sugar and reduce long-term complications.
What could go wrong: This is a small pilot study with only 50 participants, so results may not apply widely. The device must be replaced every 14 days, which could be burdensome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES DIABETES MELLITUS DIABETES TYPE 2

Contacts and locations

Locations

University Medical Center
RECRUITING

New Orleans, Louisiana, 70112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.